1. Bhasin, S, Brito, JP, Cunningham, GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline. J Clin Endocrinol Metabol. 2018;103:1715-1744.
Google Scholar | Crossref | Medline2. Food and Drug Administration . Drug Safety Communications: FDA Evaluating Risk of Stroke, Heart Attack and Death with FDA-Approved Testosterone Products (January 2014). Silver Spring, MD: Food and Drug Administration. https://www.fda.gov/media/88140/download#:∼:text=%5B01%2D31%2D2014%5D,taking%20FDA%2Dapproved%20testosterone%20products. Accessed September, 2020.
Google Scholar3. Diem, SJ, Greer, NL, MacDonald, R, et al. Efficacy and safety of testosterone treatment in men: an evidence report for a clinical practice guideline by the American college of physicians. Ann Intern Med. 2020;172:105-118.
Google Scholar | Crossref | Medline4. Glueck, CJ, Goldenberg, N, Wang, P. Thromboembolism peaking 3 months after starting testosterone therapy: testosterone-thrombophilia interactions. J Invest Med. 2018;66:733-738.
Google Scholar | Crossref | Medline5. Houghton, DE, Alsawas, M, Barrioneuvo, P, et al. Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2018;172:94-103.
Google Scholar | Crossref | Medline6. Jones, SD, Dukovac, T, Sangkum, P, Yafi, FA, Hellstrom, WJG. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sex Med Rev. 2015;3:101-112.
Google Scholar | Crossref | Medline7. Ayele, HT, Brunetti, VC, Renoux, C, Tagalakis, V, Filion, KB. Testosterone replacement therapy and the risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. Thromb Res. 2021;199:123-131.
Google Scholar | Crossref | Medline8. Walker, RF, Zakai, NA, Maclehose, RF, et al. Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism. JAMA Intern Med. 2020;180:190-197.
Google Scholar | Crossref | Medline9. Food and Drug Administration . Androgel Package Insert. Silver Spring, MD: Food and Drug Administration. . Accessed 11 June 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021015s036lbl.pdf.
Google Scholar10. Shatzel, JJ, O’Donnell, M, Olson, SR, et al. Venous thrombosis in unusual sites: a practical review for the hematologist. Eur J Haematol. 2019;102:53-62.
Google Scholar | Crossref | Medline11. Ageno, W, Beyer-Westendorf, J, Garcia, DA, Lazo-Langner, A, McBane, RD, Paciaroni, M. Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis. 2016;41:129-143.
Google Scholar | Crossref | Medline | ISI12. Kearon, C, Akl, EA, Ornelas, J, et al. Antithrombotic therapy for VTE disease. Chest. 2016;149:315-352.
Google Scholar | Crossref | Medline | ISI13. Cohen, D, Berger, SP, Steup-Beekman, GM, et al. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378:2010-2021.
Google Scholar | Crossref | Medline14. Amjad, W, Khatoon, S, Tarasaria, T, Sharifova, G. Portal vein thrombosis due to an increase in dose of testosterone in a young man with Klinefelter syndrome. Cureus. 2017;9:e1823.
Google Scholar | Medline15. Poirier-Blanchette, L, Koolian, M, et al. Testosterone replacement therapy causing extensive portal and mesenteric vein thrombosis. Am J Med. 2021.
Google Scholar | Crossref | Medline16. Katz, H, Popov, E, Bray, N, et al. Mesenteric vein thrombosis caused by secondary polycythemia from AndroGel. BMJ Case Rep. 2014.
Google Scholar | Crossref17. Campitruz, MZ, Ortiz-Figueroa, LT, Santiago, E. Portomesenteric venous thrombosis in a postmenopausal female with testosterone implant: a case report. J Med Case Rep. 2021;15(1):280.
Google Scholar | Crossref | Medline18. Garcia‐Cortes, M, Lucena, MI, Pachkoria, K, et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug‐induced liver injury. Aliment Pharmacol Ther. 2008;27:780-789.
Google Scholar | Crossref | Medline19. Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Therapeut. 1981;30:239-245.
Google Scholar | Crossref | Medline | ISI20. Sharma, AM, Zhu, D, Henry, Z. Portal vein thrombosis: when to treat and how? Vasc Med. 2016;21:61-69.
Google Scholar | SAGE Journals | ISI21. Kearon, C, Akl, EA, Comerota, AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:E419S-E496S.
Google Scholar | Crossref | Medline | ISI22. Janczak, DT, Mimier, MK, McBane, RD, et al. Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location. Mayo Clin Proc. 2018;93:40-47.
Google Scholar | Crossref | Medline